Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Combining computerized tomography with fluorodeoxyglucose positron emission tomography images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

ASTRO develops new thoracic radiotherapy guideline

The American Society for Radiation Oncology has developed a guideline for the use of external beam radiation therapy, endobronchial brachytherapy and concurrent chemotherapy to palliate thoracic symptoms caused by advanced lung cancer. The guideline will be published in Practical Radiation Oncology, an official journal of ASTRO.

28 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Nutlin-3a molecules stimulate signal to induce cell death and senescence in brain cancer

Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53.

21 Apr 2011

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

NYU Langone Medical Center announced today the U.S. Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sandra and Edward Meyer Professor and Chair of the Department of Radiation Oncology a $4.5 million Multi-Team Award to conduct novel breast cancer research.

21 Apr 2011

RaySearch receives order for its RayStation system from RISO

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from RISO, the Radiotherapeutic Institute in Deventer, the Netherlands.

19 Apr 2011

Varian Medical Systems launches new brachytherapy applicator

Varian Medical Systems is introducing a new brachytherapy applicator for treating endometrial cancer patients after a hysterectomy. The Capri applicator, aimed at increasing patient comfort and allowing clinicians to better sculpt the radiotherapy dose, is being exhibited this week at the annual American Brachytherapy Society meeting in San Diego.

15 Apr 2011

Targeted photodynamic therapy eradicates some models of cancer

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer.

12 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Soy isoflavones can improve radiotherapy for lung cancer cells

A component in soybeans increases radiation's ability to kill lung cancer cells, according to a study published in the April issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

1 Apr 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

Radiotherapy News and Research

Further Reading

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

New PET imaging clinical trial to improve early esophageal, lung cancer detection

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

ASTRO develops new thoracic radiotherapy guideline

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Nausea and vomiting are most feared of all chemotherapy-related side effects

Nutlin-3a molecules stimulate signal to induce cell death and senescence in brain cancer

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

RaySearch receives order for its RayStation system from RISO

Varian Medical Systems launches new brachytherapy applicator

Targeted photodynamic therapy eradicates some models of cancer

Novelos Therapeutics acquires Cellectar

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Soy isoflavones can improve radiotherapy for lung cancer cells

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News